Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients
- PMID: 9632123
- DOI: 10.1002/(SICI)1096-9136(199806)15:6<485::AID-DIA610>3.0.CO;2-Y
Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients
Abstract
GLP-1, an incretin hormone of the enteroinsular axis with insulinotropic and glucagonostatic activity, is secreted after nutrient ingestion. GLP-1 is mainly produced by intestinal L-cells in the lower gastrointestinal tract (GIT); simple carbohydrates are absorbed in the upper GIT and alpha-glucosidase inhibition leads to augmented and prolonged GLP-1 release in normal subjects. In a cross-over study, 100 mg acarbose or placebo was administered simultaneously with 100 g sucrose to 11 hyperglycaemic Type 2 diabetic patients poorly controlled with diet and sulphonylureas. Plasma levels of GLP-1, insulin, C-peptide, glugacon, GIP, glucose and H2-exhalation were measured over 6 h. Differences in the integrated responses over the observation period were evaluated by repeated measurement analysis of variance with fasting values used as covariates. With acarbose, sucrose reached the colon 60-90 min after ingestion as indicated by a significant increment in breath hydrogen exhalation (p = 0.005). After an early GLP-1 increment 15 min after sucrose under both conditions, GLP-1 release was prolonged in the acarbose group (p = 0.001; significant from 210 to 360 min.). Initially (0-150 min), glucose (p = 0.001), insulin (p = 0.001), and GIP (p < 0.001) were suppressed by acarbose, whereas later there were no significant differences. Glucagon levels were higher with acarbose in the last 3 h of the 6 h observation period (p = 0.02). We conclude that in hyperglycaemic Type 2 diabetic patients, ingestion of acarbose with a sucrose load leads to elevated and prolonged GLP-1 release.
Similar articles
-
alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.Diabet Med. 2005 Apr;22(4):470-6. doi: 10.1111/j.1464-5491.2005.01451.x. Diabet Med. 2005. PMID: 15787675 Clinical Trial.
-
Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.Exp Clin Endocrinol Diabetes. 1997;105(4):187-95. doi: 10.1055/s-0029-1211750. Exp Clin Endocrinol Diabetes. 1997. PMID: 9285204 Review.
-
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.Diabetologia. 2002 Aug;45(8):1111-9. doi: 10.1007/s00125-002-0878-6. Epub 2002 Jul 4. Diabetologia. 2002. PMID: 12189441
-
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.Diabetes. 2008 Mar;57(3):678-87. doi: 10.2337/db07-1124. Epub 2007 Dec 5. Diabetes. 2008. PMID: 18057091
-
The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S288-303. doi: 10.1055/s-2001-18589. Exp Clin Endocrinol Diabetes. 2001. PMID: 11460578 Review.
Cited by
-
Higher mitochondrial DNA copy number is associated with metformin-induced weight loss.Commun Med (Lond). 2023 Feb 18;3(1):29. doi: 10.1038/s43856-023-00258-0. Commun Med (Lond). 2023. PMID: 36806755 Free PMC article.
-
Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice.BMC Microbiol. 2019 Jun 13;19(1):130. doi: 10.1186/s12866-019-1494-7. BMC Microbiol. 2019. PMID: 31195972 Free PMC article.
-
Glucose supply and insulin demand dynamics of antidiabetic agents.J Diabetes Sci Technol. 2010 Mar 1;4(2):365-81. doi: 10.1177/193229681000400219. J Diabetes Sci Technol. 2010. PMID: 20307399 Free PMC article.
-
Cardiovascular risk stratification and management in pre-diabetes.Curr Diab Rep. 2014 Jun;14(6):493. doi: 10.1007/s11892-014-0493-1. Curr Diab Rep. 2014. PMID: 24743942 Review.
-
Targeted intestinal delivery of incretin secretagogues-towards new diabetes and obesity therapies.Peptides. 2018 Feb;100:68-74. doi: 10.1016/j.peptides.2017.11.008. Peptides. 2018. PMID: 29412834 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical